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The COVID-19 pandemic has led to an abrupt transition to virtual healthcare in pregnancy, 
to reduce dependence on hospital-based care and minimise COVID-19 infection, which 
appears to carry similar risk in pregnancy1. This is true for all women, including the 
approximately 10% who have pregnancy hypertension and receive specialist hypertension 
care2.  
Specific guidance for hypertensive pregnant women has been provided in some 
jurisdictions3, and focussed on provision of self-monitoring at home and virtual consultation 
whenever possible. This is most likely for women with chronic or gestational hypertension, 
who can self-monitor BP at home, undertake proteinuria testing, and have only remote 
review with the maternity care team unless otherwise attending hospital (such as for 
maternal blood tests or fetal ultrasound). While women with pre-eclampsia may be cared for 
as outpatients, they are still advised to attend face-to-face visits frequently3. Regardless, key 
aspects of pregnancy hypertension care must be provided for all hypertensive pregnant 
women and within the constraints of the current health care system. 
• Measure BP with a device validated for use in pregnancy 
While home blood pressure monitoring (HBPM) has been undertaken informally in maternity 
care, the COVID-19 pandemic has facilitated rapid implementation of this practice. HBPM is 
a key part of a remote monitoring strategy in pregnancy, and recommended based on 
acceptability to women, widespread informal use, and lack of safety concerns4. Women with 
chronic hypertension are ideally-suited for HBPM and may have practiced this before 
pregnancy. Women with gestational hypertension are also capable of undertaking HBPM5. 
As a national example, HBPM is being facilitated for use in the UK. First, the RCOG provides 
guidance on BP devices appropriate for home use and validated in pregnancy and pre-
eclampsia specifically (https://STRIDEBP/org/BP-monitors), along with clear patient 
instructions for BP device loans and details of monitoring4. Second, UK government 
agencies have procured and validated BP monitors for purchase by hospitals, for domiciliary 
use by hypertensive pregnant women. Third, use of BP apps is being encouraged to 
facilitate recording and transmission of BP values to care-providers; K2 Hampton is the only 
pregnancy BP app certified as a Class I Medical Device in the UK and extensively evaluated 
within the NHS (https://www.k2ms.com)5-7. 
It is unclear whether HBPM targets should be the same as those used in the clinical setting, 
for either screening (among previously normotensive women, whether they are at low- or 
increased-risk of pre-eclampsia) or management among hypertensive women. While BP 
measured at home (vs. the clinic) may be lower, at least among hypertensive women (by up 
to 16mmHg systolic and 7mmHg diastolic), there is wide variation between women8. As 
such, it is difficult to justify routine use of lower target BP values at home.  
The implications on pregnancy outcomes and costs of a reliance on HBPM to replace many 
clinic measurements are unknown. Preliminary evidence for hypertensive women attending 
specialist care suggests that use of HBPM and a BP app may reduce outpatient health care 
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utilisation (even among women with recently-diagnosed gestational hypertension5) and 
costs7. 
• Assess the risk of pre-eclampsia at antenatal care booking and prescribe aspirin for 
women at increased risk 
Low-dose aspirin decreases the risk of pre-eclampsia, particularly pre-term pre-eclampsia, 
when 150mg/d of aspirin is administered to women identified as being at high-risk based on 
first trimester multivariable screening9. While concerns have been raised about use of non-
steroidal anti-inflammatories (NSAIDs) and an associated risk of disease progression, this 
remains unproven, and the World Health Organization considers use of NSAIDs acceptable 
for relief of COVID-19 symptoms10. The dose of aspirin for pre-eclampsia prevention is lower 
than that used to achieve anti-inflammatory effects, and there are no reports of COVID-19 
accelerated disease progression in patients so-treated. Also, it is even more important to 
decrease the risk of pre-eclampsia in this era of virtual care. 
• Treat hypertension (BP ≥140/90mmHg) with antihypertensive therapy 
Oral antihypertensive therapy halves the risk of severe hypertension (systematic review, 31 
trials, 3485 women)11, an outcome that warrants face-to-face assessment in all jurisdictions, 
even during COVID-19. As avoidance of unnecessary face-to-face visits is an objective goal 
during this pandemic, avoidance of severe hypertension is a particularly worthy goal during 
the COVID-19 pandemic.  
The international CHIPS Trial (Control of Hypertension In Pregnancy Study) showed that 
‘tight’ control (aiming for a target diastolic BP of 85mmHg) was better than ‘less tight’ control, 
(aiming for a target diastolic BP of 100mmHg to minimise use of antihypertensive therapy), 
not only to reduce the incidence of severe hypertension, but also that of a platelet count 
<100x109/L, and elevated liver enzymes with symptoms12. Importantly, there was no impact 
(positive or negative) of ‘tight’ control on perinatal mortality or morbidity, birthweight <10th 
centile, or preterm birth13.  
BP control was achieved by a simple algorithm of antihypertensive up- or down-titration 
(Figure 1), using single or multiple medications; practical information is available about 
progression from starting to maximum dosage, and medication combinations14. Initial 
antihypertensive therapy should be monotherapy from accepted first-line drugs; while no 
antihypertensive agent has been proven superior to others, oral labetalol (as used by the 
majority of women in CHIPS), nifedipine, and methyldopa are used most commonly in 
pregnancy11,15. As outside pregnancy, women of African or Caribbean ethnic origin would be 
expected to respond best to a calcium channel blocker based on low renin hypertension, but 
the majority still respond to oral labetalol16. Additional antihypertensive drugs should be used 
if target BP levels are not achieved with standard-dose monotherapy17, at least to a mid-
range dose; add-on drugs should be from a different drug class chosen from first-line or 
second-line options17. Table 1 presents a suggested dosing escalation protocol. 
• Define pre-eclampsia broadly and assess the risk of adverse maternal outcomes 
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Chronic (≈25%) or gestational hypertension (up to ≈35%) frequently evolves into pre-
eclampsia. Detection of this progression is why professional societies and advocacy groups 
emphasise evaluation of maternal symptoms15, and many societies have adopted a broad 
definition of pre-eclampsia that includes maternal/ fetoplacental end-organ involvement 
(including symptoms)18. 
In a systematic review of maternal risk stratification in pregnancy hypertension (32 studies), 
miniPIERS (Pre-eclampsia Integrated Estimate of Risk Score) was the only model for all 
pregnancy hypertension types. Importantly during COVID-19, miniPIERS can also be used 
for outpatients. miniPIERS has been externally validated19 and quantifies the risk of adverse 
maternal outcome by BP, symptoms, urinalysis (if performed), gestational age and parity (of 
particular importance for nulliparous women who have no prior history of ongoing 
pregnancy)19. Women at high risk have a predicted risk ≥25%, as a ‘rule-in’ test for adverse 
maternal outcome (good likelihood ratio 5.1 and correct classification 86%). 
Any woman with suspected pre-eclampsia requires a face-to-face evaluation by her 
healthcare team. While angiogenic markers have been recommended as part of this 
evaluation in the UK20, based on their good to excellent performance at ruling-out a 
diagnosis of pre-eclampsia (defined by new-onset proteinuria, within 7 days) or pre-
eclampsia requiring delivery within 14 days21-24. However, angiogenic markers may be useful 
even if women meet diagnostic criteria for pre-eclampsia; many women in ‘suspected’ pre-
eclampsia studies likely had pre-eclampsia at baseline22, and preliminary evidence suggests 
that angiogenic markers may further increase prediction of the need for delivery25 and guide 
place of care.  
• Time delivery from 37 weeks for women with pre-eclampsia 
By global consensus, women with preterm pre-eclampsia who reach 37+0 weeks, and those 
who develop pre-eclampsia at term gestational age, should be induced within 24 hours, to 
decrease the risk of maternal disease progression and complications26. While guidelines are 
not inconsistent regarding timed delivery for women with chronic or gestational hypertension, 
local standard of care should be maintained. When considering induction of labour, if a 
woman is also symptomatic with COVID-19, it may be advisable to delay the induction if 
possible3; under those circumstances, strict attention to BP control would be prudent as 
severe hypertension is the most common complication avoided by labour induction.  
• Use antenatal corticosteroids for fetal lung maturation 
Dexamethasone is being evaluated as a therapeutic intervention for COVID-19 infection 
requiring hospitalisation outside pregnancy (https://www.recoverytrial.net/). As such, there is 
no maternal harm anticipated from use of antenatal corticosteroids for acceleration of fetal 
pulmonary maturity, and many women with pre-eclampsia will require iatrogenic preterm 
birth. However, for outpatient hypertensive women prior to elective Caesarean, clinicians 
should weigh the diminishing benefits of antenatal corticosteroids with advancing gestational 
This article is protected by copyright. All rights reserved.
age up to 38+6 weeks against the risks of COVID-19 infection, as women need to attend 
hospital twice to receive the injections3. 
• Use magnesium sulphate to prevent or treat eclampsia  
There are no published reports of magnesium sulphate altering the natural history of COVID-
19 infection. As magnesium sulphate halves the risk of eclampsia incidence and recurrence, 
it should be used as normally indicated during the COVID-19 pandemic. 
• Measure BP postpartum on days 3-6 after hypertensive pregnancy 
Despite its importance, there is limited evidence to support how to use antihypertensive 
therapy postpartum27. One trial found HBPM and postnatal down-titration of 
antihypertensives improved BP control28. The most commonly-used antihypertensives, and 
most others, are acceptable for use in breastfeeding29. Given that BP rises postpartum and 
peaks on days three to six after birth by which time women have usually left hospital, and 
hypertension increases the risk of postnatal stroke30, it would be reasonable to continue 
‘tight’ BP control for the six weeks postpartum. 
While drugs that block the renin-angiotensin system may be used for postpartum 
hypertension, based on low drug levels in breastmilk, the effect of angiotensin-converting 
enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) on the natural history of 
COVID-19 has been questioned. Mechanisms have been postulated for both harmful and 
beneficial effects mediated through upregulation of membrane-bound ACE-2 by ACE 
inhibitors or ARBs31. While reassuring information is emerging32, given the greater difficulty 
in monitoring maternal serum electrolytes and creatinine during the pandemic, it may be 
prudent to avoid use of these medications postpartum until after the pandemic.   
Conclusions 
Hypertension complicates approximately 10% of pregnancies, and is a leading cause of 
maternal and perinatal morbidity and mortality worldwide. The COVID-19 crisis has rapidly 
broadened a shared model of care with women, to diagnose and remotely manage 
pregnancy hypertension. This health system transition is superimposed on significant shifts 
in thought about pre-eclampsia definitions, maternal risk stratification, and ‘tight’ BP control. 
As Winston Churchill said, “Never let a good crisis go to waste.” 
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FIGURE LEGENDS 
Figure 1: Algorithm for ‘tight’ BP control in the CHIPS trial 
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‘Tight’ control 
Target dBP 85mmHg† 
dBP 81-85mmHg 
No change 
dBP ≤80mmHg dBP >85mmHg 
STOP antihypertensive medication 
OR 
↓ dose of existing antihypertensive 
medication 
START antihypertensive medication 
OR 
↑ dose of existing antihypertensive 
medication 











Table 1: Suggested dose titration of first-line antihypertensive therapy in pregnancy 
 
BID (twice/day), BP (blood pressure) LA (long-acting), MR (modified release), QAM 
(every morning), QID (four times/day), QPM (every evening), PA (modified release), TID 
(three times/day), XL (extended release) 
* Starting doses are higher than generally recommended for adults given more rapid 
clearance in pregnancy.  
**When a medication is at high (or maximum) dosage, consider using a different 





This article is protected by copyright. All rights reserved.
